ARNI superior to ARB in reducing NT-proBNP in patients with HFmrEF/HFpEF

Name: ARNI superior to ARB in reducing NT-proBNP in patients with HFmrEF/HFpEF
Uploaded: 2023-05-25T02:00:00+00:00
Duration: 2 min 6 s
Description: ESC Heart Failure 2023 Robert Mentz presents the results of PARAGLIDE-HF, which reported greater reduction in NT-proBNP in the sacubitril/valsartan group v

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Cardiac myosin inhibitor is safe and effective in HCM in phase 2 trial
Cardiac myosin inhibitor is safe and effective in HCM in phase 2 trial
ESC Heart Failure 2023
Cardiac myosin inhibitor is safe and effective in HCM in phase 2 trial
Ahmad Masri, MD
- Ahmad Masri, MD
Remote hemodynamic monitoring improves quality of life and reduces HF hospitalizations in HF
Remote hemodynamic monitoring improves quality of life and reduces HF hospitalizations in HF
ESC Heart Failure 2023
Remote hemodynamic monitoring improves quality of life and reduces HF hospitalizations in HF
Jasper Brugts, MD, PhD
- Jasper Brugts, MD, PhD
Benefits of rapid uptitration of HF medications independent of baseline renal function
Benefits of rapid uptitration of HF medications independent of baseline renal function
ESC Heart Failure 2023
Benefits of rapid uptitration of HF medications independent of baseline renal function
Jozine ter Maaten, MD, PhD
- Jozine ter Maaten, MD, PhD
Persistent benefit with RNAi targeting TTR in patients with ATTR cardiac amyloidosis
Persistent benefit with RNAi targeting TTR in patients with ATTR cardiac amyloidosis
ESC Heart Failure 2023
Persistent benefit with RNAi targeting TTR in patients with ATTR cardiac amyloidosis
Marianna Fontana, MD, PhD
- Marianna Fontana, MD, PhD

ARNI superior to ARB in reducing NT-proBNP in patients with HFmrEF/HFpEF

Recommended

Title